The Medical Devices sector report, “Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update' provides comprehensive information about the Acquired Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Acquired Gene or Chromosome Alterations comprises of reagents employed for genetic testing to detect cancer causing/ related alterations, such as; k-ras, BRCA 1+2, Telomerase and HER-2/neu (human epidermal growth factor receptor 2).
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Acquired Gene or Chromosome Alterations comprises of reagents employed for genetic testing to detect cancer causing/ related alterations, such as; k-ras, BRCA 1+2, Telomerase and HER-2/neu (human epidermal growth factor receptor 2).
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Acquired Gene or Chromosome Alterations under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Acquired Gene or Chromosome Alterations and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Acquired Gene or Chromosome Alterations under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Acquired Gene or Chromosome Alterations - Pipeline Products under Development by Companies
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abital Pharma Pipelines Ltd
- Admera Health LLC
- Agena Bioscience Inc
- Aix-Marseille University
- Albert Ludwigs University of Freiburg
- Apteryx Imaging Inc
- Baruch S. Blumberg Institute
- Baylor College of Medicine
- bioMerieux SA
- Biotype Innovation GmbH
- Blondin Bioscience, LLC
- Cardiff Oncology Inc
- Cepheid Inc
- Children's Hospital Los Angeles
- Children's Hospital of Philadelphia
- China Medical Technologies Inc (Inactive)
- Chronix Biomedical Inc
- Columbia University
- Duke University
- Empire Genomics LLC
- Fred Hutchinson Cancer Research Center
- French National Institute of Health and Medical Research
- Garvan Institute of Medical Research
- Gencurix Inc
- Genetag Technology, Inc
- Genomic Health Inc
- GenomicTree Co Ltd
- German Cancer Research Center
- H. Lee Moffitt Cancer Center & Research Institute Inc
- Heali Ltd
- Hebrew University of Jerusalem
- Heidelberg Pharma AG
- Helmholtz Centre for Infection Research
- Inform Genomics Inc
- Institute of Cancer Research
- Interpace Biosciences Inc
- iTP Biomedica Corp
- Johns Hopkins University
- Massachusetts General Hospital
- Mayo Clinic
- McGill University
- MDNA Life Sciences Inc
- MolecularMD Corp
- Myriad International GmbH
- Nel ASA
- Northern California Institute for Research and Education
- NucleoBio Inc
- Ohio State University
- OmicsWay Corp
- Oxford Biodynamics Plc
- Oxford Cancer Biomarkers Ltd
- Pennsylvania State University
- Princess Margaret Cancer Centre
- QuantuMDx Group Ltd
- Queen's University Belfast
- Rosetta Genomics Ltd (Inactive)
- Stanford University
- Stony Brook University
- Syamala Srinivasa Life Sciences Pvt. Ltd
- Telo Genomics Corp
- The Chinese University of Hong Kong
- The University of New South Wales press Limited
- The Walter and Eliza Hall Institute of Medical Research
- TheraDiag SA
- Therawis Diagnostics GmbH
- Thrive Earlier Detection Corp
- Total Brain Ltd
- Trinity College Dublin
- University College London
- University of California San Diego
- University of Cambridge
- University of Central Florida
- University of Cologne
- University of Copenhagen
- University of Hawaii at Manoa
- University of Montreal
- University of Rochester
- University of South Carolina
- University of Southern California
- University of Strathclyde
- University of Sydney
- University of Texas Medical Branch at Galveston
- University of Washington
- Vyant Bio Inc
- Wistar Institute
- Yaathum Biotech Pvt Ltd
- Yale University